Mast Therapeutics Inc (MSTX) Downgraded to Neutral at Laidlaw
A number of other brokerages have also issued reports on MSTX. Maxim Group set a $5.00 target price on shares of Mast Therapeutics and gave the company a buy rating in a research note on Thursday, September 8th. Roth Capital reissued a buy rating and set a $8.00 target price on shares of Mast Therapeutics in a research note on Thursday, June 9th. Zacks Investment Research lowered shares of Mast Therapeutics from a buy rating to a hold rating in a research note on Tuesday, July 12th. Finally, Canaccord Genuity reissued a buy rating and set a $3.00 target price on shares of Mast Therapeutics in a research note on Thursday, July 28th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $3.33.
Shares of Mast Therapeutics (NASDAQ:MSTX) opened at 0.1328 on Wednesday. The stock’s market capitalization is $28.13 million. Mast Therapeutics has a 12 month low of $0.10 and a 12 month high of $0.71. The company’s 50-day moving average is $0.45 and its 200 day moving average is $0.38.
Mast Therapeutics (NASDAQ:MSTX) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. Equities research analysts predict that Mast Therapeutics will post ($0.21) earnings per share for the current year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. boosted its stake in shares of Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned about 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent reporting period.
Mast Therapeutics Company Profile
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.